Read Frequently Asked Questions
The Most Serious FDA 483s - How to Avoid Them
This webinar on avoiding serious FDA 483s will explain FDA's changed audit focus based on recent top 483 findings and provide practical tips on how to better prepare your company's internal audit program to avoid serious Form 483 observations.
Why Should You Attend:
Recent FDA audits indicate a shift in the top serious Form 483 observations.
This webinar will evaluate the chief areas of FDA CGMP compliance audits based on recent top 483 findings to see actual and anticipated changes in emphasis, and how to better prepare with a company's internal audit program .
This 90-minute session will provide valuable assistance to all regulated companies in evaluating their existing compliance and internal audit emphasis in light of the changed FDA focus based on recent 483 analysis, and their audit "paradigm". Such analysis allows a company to evaluate/ perform a gap analysis, and then put in place the necessary fixes to ensure continuing compliance.
Areas Covered in the Webinar:
- Recent Most Serious FDA 483s
- The "Whys"
- Root Causes
- Avoid complacency from past "good" FDA audits.
- Shifting focus
- Maximize scarce resources
- The "risk-based" phased approach
- Maintain "the edge" -- fight "entropy"
Who will Benefit:
This webinar applies to personnel/ companies in the Pharmaceutical, Medical Device, Diagnostic, Nutraceutical and Biologics fields. The employees who will benefit include:
- Senior management
- Regulatory Affairs
- Quality Assurance
All personnel involved in a U.S. FDA-regulated environment. Especially those involved in the complaing handling, non-conforming material, out-of-specification, failure investigations, root cause analysis, labeling, distribution, storage, tracking, use or regulated medical products.
John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company, with over 31 years experience, 17 as head of his own consulting company, in U.S. FDA-regulated industries. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D). In addition, John has prior experience in military, government, electronics, and aerospace. He has ptublished numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. John is a graduate of UCLA.
There has been a major shift in the emphasis of U.S. FDA CGMP compliance audits, and the resulting FDA Form 483 Observations. This change in focus has a major impact on individual compliance objectives, efforts and measurements of success. The Agency has come under increasing negative publicity due to major publicized product failures / recalls, leading to public concern over insufficient oversite of new product introductions (and grandfathered product) by means of the 510(k) system. This affects the Agency's approach to audits and their expectations for companies.
ComplianceOnline would process/provide refund only if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs."
For substitution, please email email@example.com or call +1-650-620-3937.
This training hasn't been reviewed yet.
John E Lincoln
10 Steps to Effective Risk Analysis for US FDA and ISO 14971 Compliance Risk-Based Verification and Validation Planning to Meet US FDA and ISO 13485 Requirements Change Control - Implementation and Management Validation for FDA and ISO 13485 Compliance: Pack of Two Courses